Description
Funapide is a Nav1.7 and Nav1.8 voltage-gated sodium channel inhibitor under the development by Xenon Pharmaceuticals and Teva Pharmaceutical Industries. It is applicated for the treatment of a variety of chronic painconditions, including osteoarthritis, neuropathic pain, postherpetic, neuralgia, erythromelalgia and dental pain. In July 2014, Funapide has reached phase IIb clinical trials